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IMPLEMENTING HDRS
Abstract
Problem
Depression, a mental health diagnosis, has affected about 18.5% of adults
(Villarroel & Terlizzi, 2020). Ketamine, a medication initially used as an
anesthetic, has improved depressive symptoms in individuals struggling with
treatment-resistant depression.
Method
This quality improvement (QI) project used the 17-item Hamilton Depression
Rating Scale questionnaire to assess depressive symptom changes in patients
receiving intramuscular ketamine for treatment-resistant depression. The
questionnaire was administered to patients pre-and post-intramuscular ketamine
administration. The data was collected on injections one, three, and six on each
participant’s set schedule of injections and participation period. The primary
outcomes measured were the questionnaire scores before and after the
administration of ketamine intramuscularly and the sum of the depressed mood
questions (1-3), insomnia questions (4-6), physical symptoms questions (9-11,
16), anxiety questions (9-11, 15), and insight question (17). Paired-samples ttesting analyses were performed on the collected data.
Results

The data showed that week one’s participants’ (n=14) scores significantly reduced
the following categories: depressed mood and thought, anxiety, and physical
symptoms. Week three’s (n=13) and week six’s (n=8) data showed a significant
reduction in depressed mood and thought and anxiety categories.
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Implications for Practice
This QI project provided encouraging data examining depression severity changes
after the administration of intramuscular ketamine for patients with major
depressive disorder or bipolar disorder. The results provide reassuring objective
information for providers concerned about possible medication tolerance or
misuse during treatment while ensuring providers that ketamine can be used to
effectively improve depressive symptoms.
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Visualizing Depressive Symptom Improvement: Implementing the 17-Item
Hamilton Depression Rating Scale
Depression is a serious and common medical illness that negatively affects
feelings, thoughts, and actions (American Psychiatric Association [APA], 2013). In 2019,
the Centers for Disease Control (CDC) reported that about 60 million, or approximately
18.5% of adults over 18, experience depressive symptoms (Villarroel & Terlizzi, 2020).
Of these individuals, 11.5% experience mild symptoms, 4.2% have moderate symptoms,
and 2.8% suffer from severe symptoms (Villarroel & Terlizzi, 2020).
The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) requires
individuals have five or more symptoms associated with depression before being
diagnosed with depression (APA, 2013). One of the symptoms must either be anhedonia
or depressed mood, while the remaining secondary symptoms are categorized as somatic
(physical) and non-somatic (psychosocial or behavioral) (APA, 2013). Patients who do
not respond to depression treatment are referred to as having treatment-resistant
depression (Agency for Healthcare Research and Quality [AHRQ], 2016). The AHRQ
(2016) stated treatment-resistant depression often presents in the diagnoses of major
depressive disorder (MDD) or bipolar disorder. Treatment remission is the goal for
depressed patients, achieved about 30% of the time, which leaves the other 70% of
patients with little to no depressive symptom relief (Trivedi et al., 2006). Fortunately,
ketamine, a medication used initially for anesthesia, was found to help patients with
treatment-resistant depression (Li & Vlisides, 2016).
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The N-methyl-D-aspartate (NMDA) receptor is a cellular channel found on the
dendritic spines of the postsynaptic neurons, the presynaptic axon terminals, interneurons
in the brain, and on glial cells in the brains of mammals (Conti, 1997). Glutamate, a
neurotransmitter, activates the NDMA receptor, which then creates synaptic changes;
these changes play a role in learning and memory (National Center for Biotechnology
Information, 2021). Researchers have found that individuals diagnosed with depression
do not have the central nervous system capability to effectively use glutamate (The
Mount Sinai Hospital / Mount Sinai School of Medicine, 2017). Ketamine is a
noncompetitive NMDA receptor antagonist that prevents glutamate neurotransmitters
from binding to NMDA receptors (Zorumski, 2016). Ketamine in subanesthetic doses
improves depressive symptoms by blocking the NMDA receptor by changing either the
receptor’s electric charge or shape (Zorumski, 2016).
Ketamine has two isomer forms, S (+) and R (-). Racemic ketamine is the title
given to ketamine that has both isomer forms, which can be administered intravenously
(IV), intramuscularly (IM), subcutaneously (SQ), and orally (Andrade, 2017; Molero et
al., 2018). Although the oral administration of ketamine is more convenient, IV, IM, and
SQ ketamine are more bioavailable (Andrade, 2017; Molero et al., 2018). The higher the
bioavailability of a medication route, the quicker the medication reaches a body’s
circulatory system. Ketamine IV and IM are, respectively, with onsets of action of mere
seconds and four minutes, both ideal for ketamine clinic use (Rosenbaum et al., 2021).
Despite the onset of action difference between IV and IM ketamine, researchers have
found IM ketamine to be just as successful in decreasing depressive symptoms (Chilukuri
et al., 2014; Fond et al., 2014; Harihar et al., 2013; Rot et al., 2012; Xu et al., 2015). Fond
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et al. (2014), Ghasemi et al. (2014), and Kheirabadi et al. (2014) reported ketamine not
only reduces depressive symptoms quicker, but the medication can also significantly
reduce suicidal ideations in patients with treatment-resistant depression while having
fewer cognitive side effects compared to electroconvulsive therapy.
Provider determination of the diagnosis of depression differs based on the
instrument used for assessment. While the PHQ-9 can provide a diagnosis of depression,
only the Hamilton Depression Rating Scale (HDRS) enables providers to apply a level of
severity to the diagnosis of depression (Wittkampf et al., 2009).
Before 1960, existing scales only provided information to help a provider
determine if a patient suffered with depression. Recognizing the limitations of the
existing scales, Hamilton (1960) created the Hamilton Depression Rating Scale (HDRS)
to determine the severity of depression symptoms in depressed patients. The original
HDRS Hamilton created was a 21-item questionnaire which he shortened to17-items.
After a depression diagnosis, the administration of the HDRS provides patient-rated data
to assess and define symptom severity (Sharp, 2015). The scale asks patients to selfassess and rate the severity of their depressed mood, suicidal ideations, insomnia,
agitation, anxiety, and motivation levels. At the time of development, Hamilton (1960)
found the HDRS to be especially effective at assessing treatment results.
The American Psychiatric Nurses Association (APNA) encourages administering
a depressive symptom scale before and after ketamine administration for all depression
diagnoses (Bolton et al., 2021). The purpose of this proposed quality improvement
project was to implement the use of the HDRS for the evaluation of treatment for
treatment-resistant depression patients receiving ketamine administered intramuscularly
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in a midwestern ketamine clinic. The aim of the project was to increase the amount of 17item HDRS scales used in the clinic to evaluate treatment-resistant depression by 15%.
The primary outcome measured was the HDRS ratings before and after intramuscularly
administered ketamine on treatment appointments one, three, and six. The secondary
outcomes measured were age, gender, race, and diagnosis. A study question was created
to help guide the literature search: In patients with treatment-resistant depression
receiving an IM ketamine injection, does the use of the 17-item HDRS before and after
IM ketamine administration effectively track improvements in depressive symptoms?
Literature Review
A literature search was conducted to determine what version of the HDRS would
help provide the best measurement of depressive symptom improvement in patients
receiving IM ketamine for treatment-resistant depression. The following search engines
were used: PubMed, Summons, and Google Scholar. Key search terms included
Hamilton Depression Rating Scale, HDRS, ketamine, intramuscular ketamine,
depression, and treatment-resistant depression, which yielded 6,915 results. Search
settings included: peer-reviewed journals, randomized controlled trials (RCT), research
articles, systematic reviews, and meta-analyses written in English from 1/1/2013 to
9/10/2021. Any article written before 2013 was excluded, except for three pertinent
articles. Duplicates were then removed, and a review of inclusion criteria focusing on the
age of participants, type of depressive screening tool used, and use of racemic ketamine
administration articles were reduced to a total of 53. The abstracts were read, and eight
articles were selected for review.
Depressive Symptom Rating Scales
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In 2006, a physician-researcher named Per Bech created a 6-item HDRS. Bech
(2006) compared 47 articles to provide a microanalysis of the 17-item HDRS to his 6item HDRS. The HDRS 6-item questionnaire asked patients how they were feeling
overall in the past three days. The 6-item scale asked about mood, self-satisfaction,
interest in activities, fatigue, mental slowing, and anxiety. The narrative review reported
the 6-item HDRS to be more sensitive in determining if a medication treatment improved
a patient’s depressive symptoms. Bech (2006) encouraged other researchers to compare
his 6-item HDRS to the original 21-item HDRS for a more accurate reliability conclusion
for in-practice use.
A meta-analysis was performed by Trajković et al. (2011) to determine the
reliability of the various HDRS questionnaires. A total of 409 articles were used. The
researchers concluded the original 21-item and modified HDRS questionnaires appeared
beneficial for healthcare professionals by helping provide quantitative data in patients
reporting the severity of their depressive symptoms. The team discovered a good internal
consistency between the HDRS scales. Inter-rater reliability was calculated with 14
articles with a total of 449 subjects. The results found the inter-rater reliability to be the
highest with “insomnia-early”, “suicide”, and “depressed mood,” while the weakest interrater reliability was “loss of insight” Trajković et al. (2011) also calculated the test-retest
reliability of the scales by using 11 articles totaling 729 participants. This analysis
revealed the longer the HDRS questionnaires were used between two researchers, the
lower the test-retest reliability. It was concluded the HDRS remains a reliable
measurement in patients with depression, and further research comparing the sensitivity
of the six and 17-item HDRS should be performed (Trajković et al., 2011).
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Dunlop et al. (2019) completed a post hoc analysis to compare the sensitivity of
the 6-item and 17-item HDRS. The study included 1,541 patients in a 24-week trial
conducted within 60 primary care and psychiatry specialty clinics in the United States.
Patients were enrolled if they were diagnosed with MDD and reported an inadequate
response to previous depressive treatments. A randomized control trial was created that
compared two different prescribing methods for patients struggling with MDD. Both
methods were found to be beneficial by using the 6-item and 17-item HDRS
questionnaires. Furthermore, the study’s analyses found the 6-item scale more beneficial
in gauging the improvement of depressive symptoms through pharmacological use.
However, since the 6-item scale uses the past three days as a time frame, the 17-item
Hamilton scale provides better information on how a rapid treatment improves depressive
symptoms. The researchers recommended the HDRS scales be compared to other
depressive symptom scales to determine which scale is more reliable (Dunlop et al.,
2019).
Carrozzino et al. (2020) performed a comprehensive review of 203 articles to
determine which versions of the HDRS were more reliable, valid, and sensitive to change
than
other depressive symptom scales. When the HDRS 17-item scale was compared to the
Beck Depression Inventory (BDI), results showed the 17-item HDRS was more sensitive
to depression symptom changes than the BDI. The HDRS 6-item scale was more
sensitive to symptom change than the Montgomery-Asberg Depression Rating Scale
(MADRS). The HDRS scales were determined to be valid, sensitive, and reliable if
researchers structured the scales. Structured scales use the same questions for every
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patient. The researchers concluded the 17-item HDRS should be used to differentiate
levels of severity and depressive symptoms of patients throughout a specific treatment. In
contrast, the 6-item HDRS should be used when determining the efficacy of active
treatment compared to placebo (Carrozzino et al., 2020).
Incorporation of HDRS with Ketamine Therapy
Several studies have validated the use of the HDRS for clinician use in measuring
ketamine therapy results. The HDRS can help clinicians identify rapid changes in a
patient’s depression symptoms. Additionally, with the APNA’s encouragement of using a
depressive symptom scale before and after administering ketamine, use of the HDRS for
ketamine therapy is a viable strategy for depression treatment (Berman et al., 2000;
Carrozzino et al., 2020; Chilukuri et al., 2014; Ghasemi et al., 2014; Harihar et al., 2013;
Katalinic et al., 2013; Kheirabadi et al., 2020).
Berman et al. (2000) conducted a study comparing patients receiving ketamine to
others receiving saline. The researchers used the HDRS to determine how each treatment
reduced depressive symptoms. This randomized, double-blind trial included seven
subjects diagnosed with major depression. Three participants who received saline and
three of the four participants who received ketamine were included in the data collection
due to one participant not completing both ketamine administrations. Measurements of
treatment, time after administration, and medication efficacy were analyzed. On average,
the HDRS scores of the patients who received ketamine were reduced by about 50%
compared to no reduction made in the patients who received saline. In addition, the
HDRS was able to provide researchers with statistically significant information on what
categories improved after ketamine administration. It was concluded that ketamine is an
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effective way to reduce depressive symptoms; however, due to the small population, the
researchers encouraged others to explore the benefits and efficacy of ketamine (Berman
et al., 2000).
Chilukuri et al. (2014) created a study “to compare the safety, tolerability, and
efficacy of intramuscular versus intravenous ketamine in major depression”. This
randomized parallel study had a total of 27 subjects. All subjects had MDD as a diagnosis
and were separated into three groups of nine. Ketamine was administered to each group
in a dose of either 0.5mg/kg IV, 0.5mg/kg IM, or 0.25mg/kg IM. The HDRS was used
before administration, two hours after administration, and four days after administration
to assess the tolerability and efficacy the three groups had with ketamine. The researchers
graded patients as non-responders (an HDRS score less than 25% from baseline), partial
responders (if the HDRS score was reduced between 26 and 49% from baseline), and
responders (an HDRS score reduction of 50% or more from baseline). Results showed
that by using the HDRS, researchers were able to determine that all groups were
responders to the ketamine 0.5mg/kg IV, 0.5mg/kg IM, or 0.25mg/kg IM treatment with a
reduction of the HDRS scores at 58.86%, 60.29%, and 57.36%, respectively. With IM
ketamine being just as effective, the smaller IM dosage provides a safer dosage amount
for providers to administer while achieving the same depressive symptom reduction
benefits as IV ketamine (Chilukuri et al., 2014).
Katalinic et al. (2013) performed a comprehensive narrative review to determine
the safety and efficacy of subanesthetic doses of ketamine to treat depression. Eleven of
the 20 studies reviewed used the HDRS to determine subjects’ symptomatic
improvement. The HDRS was able to show researchers how ketamine can significantly
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reduce depressive symptoms by quantifying qualifiable data. Unfortunately, not everyone
responded to ketamine treatment. According to the review, 70 to 80% of patients reported
ketamine as a successful treatment for their depression. Although ketamine provided
rapid relief for these successful treatments, the maximum amount of time reported for
ketamine to help was one month unless ketamine administrations were repeated to
maintain patients’ symptomatic improvement. Frequently repeated ketamine
administrations occurred. Although IM administration of ketamine has not been
providers’ top choice for patients struggling with depression, it has improved depressive
symptoms, which can be shown by HDRS questionnaire scores administered before and
after treatment. Future research was encouraged to focus on identifying predictors of
response, such as clinical, genetic, and environmental, examining various routes and
dosing regimens, and strategies to maintain the antidepressant response (Katalinic et al.,
2013).
Similarly, Kheirabadi et al. (2020) created a pilot study to compare oral and IM
ketamine treatment efficacy to electroconvulsive therapy in patients diagnosed with
major depressive disorder. Forty-five participants, 22 males and 23 females between 20
and 70 years of age, were divided equally into three groups. Each group received either
0.5mg/kg of IM ketamine, 1mg/kg of oral ketamine, or electroconvulsive therapy. Each
treatment lasted six to nine sessions for three weeks. The HDRS and Beck Scale for
Suicidal Ideations (BSSI) were used at baseline, 24 hours, one week, two weeks, and
three weeks within the intervention to measure depressive symptoms and suicidal
ideation. The researchers reported the HDRS scores were reduced in every group and did
not go back to baseline after the treatment and each treatment significantly reduced the
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BSSI and HDRS scores from baseline. Despite each group showing a significant
reduction in depressive symptoms, the researchers did not see a significant difference
between the IM ketamine, oral ketamine, and electroconvulsive therapy treatments.
While ketamine can be easily administered to help improve depressive symptoms and

suicidal ideations, the long-term effects of this medication for the treatment of treatmentresistant depression are unknown. Providers should be aware of the risks and benefits of
any treatment offered to patients struggling with treatment-resistant depression and are
encouraged to take appropriate measures to care for them in a safe environment
(Kheirabadi et al., 2020).
Research shows the 17-item HDRS is a reliable screening tool to help provide
quantitative data for qualitative information and can assess rapid changes in depressive
symptoms. Since ketamine can rapidly improve depressive symptoms, the 17-item HDRS
is the questionnaire of choice to assess these improvements. Therefore, the APNA’s
recommendations of administering a depressive symptom scale before and after ketamine
administration for all depression diagnoses can be implemented using the HDRS.
Methods
Design
This descriptive study QI project used prospective data collection. The data
collection contained patients’ HDRS scores before and after IM ketamine administration.
Data collection occurred from February 9, 2022, through March 31, 2022.
Setting
The setting was in one of the six ketamine clinics/healthcare offices caring for
urban and rural individuals in a Midwestern state. A little over 300,000 people live in the
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area. Five employees work in the clinic: two physicians, one registered nurse, and two
office assistants. The clinic screens patients for any suicidal thoughts with a modified
Columbia-Suicide Severity Rating Scale before their IM treatment; however, it does not
have any depressive symptom severity scales to administer before and after patients’ IM
ketamine treatment.
Sampling
The sample was composed of patients receiving IM ketamine for severe
depression using a convenience sampling method. The inclusion criteria were adult
patients from ages 18 through 70 with a diagnosis of major depressive disorder or bipolar
disorder. Exclusion criteria included individuals younger than 18 years of age, inmates,
and pregnant women. Weekly, the clinic administered IM ketamine to about 15 patients,
the desired size.
Data was collected using a unique alphanumeric identifier which was created and
applied to each patient for de-identification purposes. The identifier combined the twodigit month (01), two-digit year (22), and three successive letters of the alphabet: ABC to
each patient chart creating a unique seven-digit identifier. A master list of coded
identifiers and patient names were stored in a password-protected file on the clinic’s
computer. Data collected was entered on an Excel spreadsheet and stored on the student
investigator’s password-protected laptop.
Recruitment strategies for the project included asking patients if they would be
willing to participate in a quality improvement project upon making their appointment or
right before receiving their injection. going back for their injection. Informed consent was
given to the patients who were interested in participating. A consent form was signed,
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and a $5 Amazon gift card was gifted to the individuals who completed each pre-IM
administration HDRS questionnaire, for a total of $15.
Procedure
Implementation of the HDRS versus current practice without screening was a QI
project selected by the healthcare organization, which the student primary investigator
(PI) led. The 17-item HDRS was administered just prior to the scheduled IM
administration time via a paper handout completed by the patient. The IM injection was
administered by a physician in a private room. After the patient came out of their
dissociative state, about 20 to 30 minutes after the injection, each HDRS question was
read by the physician and the HDRS questionnaire was offered to the patient via a
laminated sheet. The interviewer requested and recorded patient responses by circling the
correlating numbers to the answers provided on the paper 17-item HDRS administered
before IM ketamine administration. The pre-administration and post-administration
HDRS scores and totals for each depressive symptom segment were calculated and
documented on the final data collection sheet by the PI.
Data Collection/Analysis
The primary outcomes measured were the HDRS scores before and after the
administration of ketamine intramuscularly and the sum of the depressed mood questions
(1-3), insomnia questions (4-6), physical symptoms questions (9-11, 16), anxiety
questions (9-11, 15), and insight question (17). The 17-item HDRS scores were collected
on injections one, three, and six on each participant’s set schedule of injections and
period of participation. The secondary outcomes measured were gender, race, age, and
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diagnosis. The analysis used was the paired-samples t-test, as this analysis can assess for
significant changes in the pre- and post-HDRS and categorical scores.
Approval Process
Formal, written approval was received from the participating clinic’s founders.
Before implementation, further approval was obtained from the University of MissouriSt. Louis Institutional Review Board. Risks of this QI project included the HDRS
questionnaire asking the patients to reveal sensitive information, possibly causing distress
when reporting. Healthcare professionals were available to monitor the patients, and the
participants could have opted out of the QI project at any time. The benefits of this QI
project included the provision of an additional evaluation tool to measure changes in
depressive symptoms for patients receiving IM ketamine, and the dissemination of this
data could support ketamine as a treatment in patients with treatment-resistant depression
for wary providers.
Results
Demographics
Out of 24 patients receiving IM ketamine, 15 participants participated in this QI
project; however, one participant was dropped from the QI project related to pregnancy,
making 14 participants ranging between the ages of 25 and 68 (M = 45, SD = 12.15). A
total of nine females (64.3%), three males (21.4%), and two in the other identifying
(14.3%) participated. African American (n=1), American Indian (n=1), and Caucasian
(n=12, 85.7%) were the participants’ specified races. Participants who received IM
ketamine were being treated for depression (n=12, 85.7%) and bipolar (n=2, 14.3%). All
participants received IM ketamine from this ketamine clinic before this QI project started,
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see Figure 1 to view what identifying gender percentages are associated with treatment
diagnosis. A total of 14 participants completed week one pre- and post-HDRS
questionnaires. While 13 participants completed week three and eight participants were
able to complete the pre- and post-HDRS questionnaires though week six. Only
calculating the participants who completed all six questionnaires, the eight participants
make up 30% of the patients, surpassing the aim by 15%.
Results of the HDRS Before and After Ketamine Therapy
A paired-samples t-test was conducted to evaluate participants’ depressive
symptom severity total and categorical totals before and after IM ketamine
administration. The 17-item HDRS questionnaire scores were totaled for a pre- and postIM administration score, and each question in the HDRS was separated into five different
categories. Questions were separated based on what depressive symptom category with
which they were correlated. Category one was depressed mood and thought (questions 1 3). Category two was insomnia containing questions 4 through 6. Questions 7, 8, 12
through 14, and 16 were in category three of physical symptoms and activities of daily
living (ADL). Anxiety questions 9 through 11 and 15 were in category four, and insight,
question 17, was in category five. The paired-samples t-test compared each pre- and post17-item HDRS score and question category week by week since there were at least seven
days between injections, creating a washout period. A washout period is a duration in
which research participants do not receive any treatment, and the effects of the previous
treatment are presumed to be eliminated (Segen, 2011).
The literature review above indicated ketamine was a successful treatment in
patients with treatment-resistant depression. It also mentioned how the 17-item HDRS

IMPLEMENTING HDRS

18

scale was the best depression symptom severity scale assessment for a specific treatment
while being a more reliable tool, especially when the tool is administered by one
provider. Only the provider, who administered the IM ketamine, administered the postHDRS to each participant making the QI data more reliable. The results within this QI
project show many relational results compared to what the literature showed. Tables 1
through 4 in the appendix provide this information while Figure 2 provides a comparison
of each category within the pre- and post-total scores on weeks 1, 3, and 6.
When week one’s total pre- and post-HDRS scores were compared, there was a
significant decrease in the total depressive scores from before (M = 18.21, SD = 8.997) to
post (M = 10.71, SD = 5.312) IM ketamine was administered with p = <.001 (two-tailed)
(Table 1). In scoring the HDRS, the higher the HDRS score is, the more severe the
participant’s depression is therefore, the IM ketamine reduced depression severity in
HDRS total scores by almost 50%. Similarly, participants’ depressed mood and thought
and anxiety scores were reduced by about 50%. While physical symptoms and ADL
scores were significantly reduced the first week with p = 0.007 (two-tailed), they were
not as significant as the pre- and post-total depressed mood and thought (category one)
and anxiety scores (category four).
Week three’s pre- and post-total HDRS, depressed mood and thought, and anxiety
scores paired-samples t-test all had a significant decrease in score totals with p = 0.001,
0.006, and <0.001, respectively, and about a 50% reduction in each category’s total score
(Table 2). Physical symptoms and ADL scores before (M = 4.77, SD = 3.086) to after (M
= 4.31, SD = 2.626) IM ketamine administration decreased slightly, but not significantly
(p = 0.165).
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The paired-samples t-test completed on week six’s pre- and post-total HDRS,
depressed mood and thought, and anxiety scores also had a significant decrease in score
totals with p ranging between 0.003 and 0.014 with close to about a 50% reduction in
scores after the administration of IM ketamine (Table 3). Similarly, the sixth week’s total
in physical symptoms and ADL scores did not significantly decrease with p = 0.118.
After assessing the total scores of weeks one, three, and six, it was determined
that week one’s pre- and post-total HDRS scores differed from week six’s pre- and posttotal HDRS scores. A paired-samples t-test was used to determine if there was a
significant difference (Table 4). There was a significant decrease when week one’s pre
ketamine total HDRS scores (M = 20.25, SD = 6.519) were compared to week six’s pre
ketamine total HDRS scores (M = 16.63, SD = 6.927) with t (7) = 4.396 and p = 0.036
(two-tailed). Every week’s pre- and post-score analysis of insomnia and insight could not
be performed due to no change in the reporting data as participants did not have a chance
for insomnia reassessment in the hour they were at the clinic and the insight about their
condition was stable.
Discussion
The clinic’s founders wanted to begin an assessment of depressive symptom
severity for patients receiving IM ketamine to provide best patient practice while
assessing a patient’s depressive symptoms on a weekly basis. This six-week QI project
provided encouraging data examining depression severity changes after the
administration of IM ketamine for patients with major depressive disorder or bipolar
disorder. The literature evidence of ketamine improving depressive symptoms and the QI
data coincided with each other, despite the project’s participants having prior treatment
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establishment. The results provide reassuring objective information for providers who are
concerned about possible medication tolerance or misuse during treatment. Although the
data above provided encouraging information, there were many limitations of this project
which included: time frame of project, sample size, and type of questionnaire.
Due to the university’s institutional review board needing to review this project in
depth related to sensitive matter, this project started a month later than anticipated.
Between the later start date and the completion date preventing six participants from
completing all data collection dates based on the participants own ketamine schedule. If
the project’s time-period had the planned three months to complete the project, each data
point would have had the same sample size in each calculation.
Unfortunately, the largest limitation of this project was the sample size.
Overlooking the small population receiving IM ketamine in the clinic, a total of 14
participants were included in this study. Of the 14 participants, only 13 completed week
three’s questionnaires due to the clinic being busier and a questionnaire was forgotten
about. Due to time constraints, only eight participants were able to complete every
questionnaire. Small population sizes can impact effect size by skewing data results,
creating a false data correlation with the pre and post IM ketamine 17-item HDRS scores.
Although the questionnaire chosen for this project due to the literature results
comparing the 17-item HDRS to other scales assessing depressive symptom severity, the
17-item HDRS was originally created for a clinician tool during inpatient assessments.
The 17-item HDRS was a tool created in the 1960’s and uses medical terminology that is
not patient friendly (i.e., retardation, somatic, and hypochondriasis). Recalling the
methods portion of this project, participants completed the pre HDRS questionnaire while
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a provider interviewed the patient post IM ketamine administration. Despite the
questionnaire being a successful tool in assessing depressive symptom severity in an
inpatient setting, the 17-item HDRS ultimately made more work for the provider as
medical terminology and the questionnaire’s inpatient intended use was not ideal for this
outpatient QI project or patient participation.
Conclusion
This QI project provides practice information and encouraging data for any
ketamine clinic who does not perform pre and post surveys assessing depressive
symptom severity in patients receiving ketamine for major depressive disorder or bipolar
disorder. Assessing depressive symptom severity by turning something subjective into
objective data, providers can determine the success of depression treatment while
following encouraged guidelines from associations like the APA and APNA.
The Doctor of Nursing Practice (DNP) degree track can prepare practitioners to
easily assess areas of improvement and create a plan, do, study, act (PDSA) cycle to
ultimately improve patient care and practice settings. Any QI project turns evidencebased practice information into quality practice data and creates learning opportunities in
healthcare. This project provided the opportunity to collaborate with other healthcare
providers while gaining more insight on an interesting treatment to complex but common
diagnoses.
Future research recommendations would be to compare the reliable inpatient 17item HDRS scale with outpatient depressive symptom scales in patients receiving
ketamine and to perform a quality improvement project assessing a patient-orientated
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outpatient depressive symptom severity scale such as the Quick Inventory of Depressive
Symptomatology- Self Report questionnaire.
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Appendix
Table 1
Week One’s Paired-Samples T-Test
Paired Difference

Paired
test

HDRS
Total
ScorePre
HDRS
Total
ScorePost
DMTPre
DMTPost
Phy.
Sx/ADLs
- Pre
Phy.
Sx/ADLs
- Post
AnxietyPre
AnxietyPost
Insomnia
and
InsightPre/Post

Mea
n

Std.
Deviatio
n

18.2
1

8.997

10.7
1

5.312

3.14

2.413

0.93

1.141

6.14

3.527

5.00

2.660

6.00

3.162

1.93

1.859

95%
Confidence
Interval of the
Difference
Lowe Upper
r

Mea
n

Std.
Deviatio
n

Std.
Error
Mea
n

t

df

7.50
0

5.155

1.37
8

4.523

2.21
4

2.326

0.62
2

1.14
3

1.351

4.07
1

3.050

10.47
7

5.44
3

1
3

0.871

3.558

3.56
1

1
3

0.003

0.49
4

0.36
1

0.363

1.923

3.16
6

1
3

0.007

0.43
5

0.81
5

2.310

5.832

4.99
5

1
3

Data unavailable due to no change in the reporting data

Sig.
(2tailed
)

<
0.001

<
0.001

eta

0.69
5

0.65
7
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Table 2
Week Three’s Paired-Samples T-Test
Paired Difference

Paired
test

HDRS
Total
ScorePre
HDRS
Total
ScorePost
DMTPre
DMTPost
Phy.
Sx/ADLs
- Pre
Phy.
Sx/ADLs
- Post
AnxietyPre
AnxietyPost
Insomnia
and
InsightPre/Post

Mea
n

Std.
Deviatio
n

12.5
4

6.476

7.62

4.407

2.00

1.683

0.46

0.776

4.77

3.086

4.31

2.626

3.77

2.315

0.85

1.463

95%
Confidence
Interval of the
Difference
Lowe Uppe
r
r

Mea
n

Std.
Deviatio
n

Std.
Error
Mea
n

t

df

Sig.
(2tailed
)

eta

4.92
3

4.153

1.15
2

2.414

7.432

4.27
5

1
2

0.001

0.60
3

1.53
8

1.664

0.46
2

0.533

2.544

3.33
3

1
2

0.006

0.48
1

0.46
2

1.127

0.31
2

0.219

1.142

1.47
7

1
2

0.165

0.15
4

2.92
3

2.290

0.63
5

1.539

4.307

4.60
3

1
2

<
0.001

0.63
8

Data unavailable due to no change in the reporting data
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Table 3
Week Six’s Paired-Samples T-Test
Paired Difference

Paired
test

HDRS
Total
ScorePre
HDRS
Total
ScorePost
DMTPre
DMTPost
Phy.
Sx/ADLs
- Pre
Phy.
Sx/ADLs
- Post
AnxietyPre
AnxietyPost
Insomnia
and
InsightPre/Post

Mea
n

Std.
Deviatio
n

16.6
3

6.927

9.63

4.955

2.88

2.416

1.38

2.066

6.63

2.200

5.38

2.200

5.25

2.712

1.50

1.604

95%
Confidence
Interval of the
Difference
Lowe Upper
r

Mea
n

Std.
Deviatio
n

Std.
Error
Mea
n

t

d
f

Sig.
(2tailed
)

eta

7.00
0

4.504

1.59
2

3.235

10.76
5

4.39
6

7

0.003

0.73
4

1.50
0

1.309

0.46
3

0.405

2.595

3.24
0

7

0.014

0.60

1.25
0

1.982

0.70
1

0.407

2.907

1.78
4

7

0.118

0.31
2

3.75
0

3.012

1.06
5

1.232

6.268

3.52
2

7

0.010

0.63
9

Data unavailable due to no change in the reporting data

32

IMPLEMENTING HDRS
Table 4
Comparing Week 1 Data to Week 6 Total Pre-Post HDRS Scores
Paired Difference

Paired
test

Wk 1:
HDR
S
Total
ScorePre
Wk 6:
HDR
S
Total
ScorePre
Wk 1:
HDR
S
Total
ScorePost
Wk 6:
HDR
S
Total
ScorePost

Mea
n

Std.
Deviatio
n

20.25

6.519

16.63

6.927

12.13

4.824

9.63

4.955

95%
Confidence
Interval of the
Difference
Lowe Uppe
r
r

Mea
n

Std.
Deviatio
n

Std.
Error
Mea
n

3.625

3.962

1.401

0.313

2.500

2.673

0.945

0.266

t

d
f

Sig.
(2tailed
)

eta

6.937

2.58
8

7

0.036

0.48
9

4.734

2.64
6

7

0.033

0.50
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Figure 1
Identifying Gender Percentages in Treatment Diagnoses

Other Identifying
17%

Male
16%

Other Identifying
0%
Male
Female
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Male
50%

Female
Other Identifying

Female
67%

Note. The interior circle represents the total percentages of identifying genders receiving
treatment for Major Depressive Disorder while the exterior circle provides the total
percentages of identifying genders receiving IM ketamine for Bipolar Depression.
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Figure 2
Comparing Week 1, 3, and 6 Total Scores and Categories
300
250
200
150
100

50
0
Week 1 Pre
Total

Week 1 Post
Total
Dmt

Week 3 Pre
Total
Insomnia

Physx

Week 3 Post
Total
Anxiety

Week 6 Pre
Total

Week 6 Post
Total

Insight

Note. This figure represents the sum of each participant’s total scores for each week’s pre
and post totals. Each color represents one of the five categories which make up the HDRS
questionnaire. As a reminder, week one had 14 participants, week three had 13
participants, and week six had 8 participants. The abbreviation Dmt stands for depressed
mood and thought, category one.

